A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer

Part of paid clinical trials in Tampa, Florida.

Sponsor
Sutro Biopharma, Inc.
Study ID
NCT05200364
Phase
PHASE1
Status
Terminated

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • STRO-002 — DRUG
    intravenous antibody drug conjugate
  • Bevacizumab — DRUG
    anti-VEGF agent

Study Details

Phase 1 trial to study the safety, pharmacokinetic and Preliminary Efficacy of STRO-002 in combination with Bevacizumab.

Key Dates

First listed
Jan 20, 2022
Start date
Mar 22, 2022
Status verified
Nov 2024
Primary completion
Jun 1, 2025
Completion
Jun 1, 2025

Study Design

Enrollment
58 participants (actual)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental :STRO-002 treatment in combination with Bevacizumab
    Dose Escalation: STRO-002 at increasing dose levels plus bevacizumab at 15 mg/kg Dose Expansion: STRO-002 at RP2D plus bevacizumab at 15 mg/kg

Primary Outcome Measure

Part 1 - Safety and tolerability of STRO-002/bevacizumab as a combination therapy [ Time Frame: From baseline through end of study (approximately 24 months) ]

Locations (6)

FacilityCityStateZIPSite coordinators
University of South Florida,TampaFlorida33612-
Thomas Jefferson UniversityPhiladelphiaPennsylvania19017-
University of PennsylvaniaPhiladelphiaPennsylvania19104-
Tennessee OncologyNashvilleTennessee37203-
Virginia Cancer SpecialistsFairfaxVirginia22031-
Medical College of WisconsinMilwaukeeWisconsin53226-

Find similar trials in Tampa, FL

By condition

Related Studies